EA201401276A1 - Способы с использованием хелатных комплексов олигонуклеотидов - Google Patents

Способы с использованием хелатных комплексов олигонуклеотидов

Info

Publication number
EA201401276A1
EA201401276A1 EA201401276A EA201401276A EA201401276A1 EA 201401276 A1 EA201401276 A1 EA 201401276A1 EA 201401276 A EA201401276 A EA 201401276A EA 201401276 A EA201401276 A EA 201401276A EA 201401276 A1 EA201401276 A1 EA 201401276A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oligonucleotide
ways
chemical complexes
complexes
chemical
Prior art date
Application number
EA201401276A
Other languages
English (en)
Other versions
EA034799B1 (ru
Inventor
Мишель Базине
Эндрю Вайан
Original Assignee
Репликор Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Репликор Инк. filed Critical Репликор Инк.
Publication of EA201401276A1 publication Critical patent/EA201401276A1/ru
Publication of EA034799B1 publication Critical patent/EA034799B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)

Abstract

Описываются фармацевтические композиции и способы для лечения вирусных инфекций, гиперхолестеринемии, гипертриглицеридемии, болезни Альцгеймера, прионных заболеваний и мышечной дистрофии Дюшенна хелатными комплексами олигонуклеотидов.
EA201401276A 2012-05-18 2013-05-17 Способ лечения hbv-инфекции с использованием хелатных комплексов олигонуклеотидов EA034799B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648694P 2012-05-18 2012-05-18
PCT/CA2013/050378 WO2013170385A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex methods

Publications (2)

Publication Number Publication Date
EA201401276A1 true EA201401276A1 (ru) 2015-04-30
EA034799B1 EA034799B1 (ru) 2020-03-23

Family

ID=49581827

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201401276A EA034799B1 (ru) 2012-05-18 2013-05-17 Способ лечения hbv-инфекции с использованием хелатных комплексов олигонуклеотидов

Country Status (37)

Country Link
US (1) US9616083B2 (ru)
EP (1) EP2849760B1 (ru)
JP (2) JP6294308B2 (ru)
KR (1) KR101975915B1 (ru)
CN (1) CN104379152B (ru)
AR (1) AR091065A1 (ru)
AU (1) AU2013262415B2 (ru)
BR (1) BR112014028568B1 (ru)
CA (1) CA2873526C (ru)
CL (1) CL2014003135A1 (ru)
CO (1) CO7131388A2 (ru)
CR (1) CR20140522A (ru)
CU (1) CU20140132A7 (ru)
CY (1) CY1122856T1 (ru)
DK (1) DK2849760T3 (ru)
DO (1) DOP2014000263A (ru)
EA (1) EA034799B1 (ru)
EC (1) ECSP14027542A (ru)
ES (1) ES2767333T3 (ru)
HR (1) HRP20200045T1 (ru)
HU (1) HUE047456T2 (ru)
IL (1) IL235402B (ru)
IN (1) IN2014DN08982A (ru)
LT (1) LT2849760T (ru)
MX (1) MX360626B (ru)
MY (1) MY168209A (ru)
NZ (1) NZ701931A (ru)
PH (1) PH12014502484B1 (ru)
PL (1) PL2849760T3 (ru)
PT (1) PT2849760T (ru)
RS (1) RS59914B1 (ru)
SG (1) SG11201407261XA (ru)
SI (1) SI2849760T1 (ru)
SM (1) SMT202000025T1 (ru)
TW (1) TWI648288B (ru)
WO (1) WO2013170385A1 (ru)
ZA (1) ZA201408082B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008317566B2 (en) 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
AU2013308045B2 (en) 2012-08-30 2018-10-04 Replicor Inc. Methods for the treatment of hepatitis B and hepatitis D infections
HRP20231400T1 (hr) * 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
AU2016250576C1 (en) 2015-04-23 2021-05-06 Geron Corporation Methods of polynucleotide preparation using multivalent cation salt compositions
JP2019507579A (ja) 2015-10-28 2019-03-22 クリスパー セラピューティクス アーゲー デュシェンヌ型筋ジストロフィーの処置のための材料および方法
WO2017106926A1 (en) * 2015-12-23 2017-06-29 Queensland University Of Technology Nucleic acid oligomers and uses therefor
CA3029772A1 (en) * 2016-07-05 2018-01-11 Biomarin Technologies B.V. Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022488A1 (en) * 1993-04-01 1994-10-13 Isis Pharmaceuticals, Inc. ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION
US20020166764A1 (en) 1997-08-12 2002-11-14 University Of Southern California Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN1694959A (zh) * 2002-09-13 2005-11-09 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
EP2330194A3 (en) * 2002-09-13 2011-10-12 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2006042418A1 (en) * 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
EP1942911A4 (en) 2005-09-29 2009-08-19 Replicor Inc THERAPEUTIC MOLECULES AND USES THEREOF
US8101585B2 (en) * 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
EP2268811A1 (en) * 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2408796B1 (en) * 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
BR112013003875B1 (pt) 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos

Also Published As

Publication number Publication date
EA034799B1 (ru) 2020-03-23
MX2014013885A (es) 2015-05-08
HK1206259A1 (en) 2016-01-08
EP2849760B1 (en) 2019-10-30
CO7131388A2 (es) 2014-12-01
TWI648288B (zh) 2019-01-21
AR091065A1 (es) 2014-12-30
IL235402A0 (en) 2014-12-31
EP2849760A1 (en) 2015-03-25
JP6294308B2 (ja) 2018-03-14
CU20140132A7 (es) 2015-02-26
CN104379152A (zh) 2015-02-25
DOP2014000263A (es) 2015-01-31
WO2013170385A1 (en) 2013-11-21
CL2014003135A1 (es) 2015-01-09
LT2849760T (lt) 2020-04-10
JP2018058853A (ja) 2018-04-12
PH12014502484B1 (en) 2021-03-31
DK2849760T3 (da) 2020-02-03
HRP20200045T1 (hr) 2020-03-20
JP2015517503A (ja) 2015-06-22
KR20150016330A (ko) 2015-02-11
US9616083B2 (en) 2017-04-11
NZ701931A (en) 2016-06-24
EP2849760A4 (en) 2015-03-25
MY168209A (en) 2018-10-15
ZA201408082B (en) 2015-12-23
PT2849760T (pt) 2020-01-24
MX360626B (es) 2018-11-12
CA2873526C (en) 2020-08-18
ES2767333T3 (es) 2020-06-17
SG11201407261XA (en) 2014-12-30
AU2013262415A1 (en) 2014-11-27
HUE047456T2 (hu) 2020-04-28
CY1122856T1 (el) 2021-05-05
CA2873526A1 (en) 2013-11-21
AU2013262415B2 (en) 2017-06-22
SMT202000025T1 (it) 2020-03-13
ECSP14027542A (es) 2015-12-31
PH12014502484A1 (en) 2015-01-12
BR112014028568A2 (pt) 2020-06-02
CR20140522A (es) 2014-12-10
SI2849760T1 (sl) 2020-03-31
US20130310445A1 (en) 2013-11-21
BR112014028568B1 (pt) 2022-02-15
IN2014DN08982A (ru) 2015-05-22
CN104379152B (zh) 2018-10-30
TW201408689A (zh) 2014-03-01
KR101975915B1 (ko) 2019-05-08
RS59914B1 (sr) 2020-03-31
IL235402B (en) 2022-01-01
PL2849760T3 (pl) 2020-05-18

Similar Documents

Publication Publication Date Title
EA201401276A1 (ru) Способы с использованием хелатных комплексов олигонуклеотидов
CL2015001358A1 (es) Potenciadores del cftr deuterados
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
PH12014501702A1 (en) Imidazopyrrolidinone compounds
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201991484A1 (ru) Лекарственные формы энзалутамида
MX350539B (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EP2841107A4 (en) CYTOTOXIC ACTIVITIES DISPOSED OF HIV RELEASING MOLECULES (CDM-HS), CYTOTOXIC EFFECT AGAINST HUMAN IMMUNE WEAKAGE VIRUS AND METHOD OF USE
CY1124345T1 (el) Συνθεσεις πολυπεπτιδιων-συμπλοκων χηλικων ενωσεων ολιγονουκλεοτιδιων και μεθοδοι
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
LT2939665T (lt) Farmacinė kompozicija, skirta živ infekcijų gydymui
EP2900259A4 (en) GLYCOSIDASE DOSAGE PLAN FOR THE TREATMENT OF INFECTION DISEASES
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
BR112015006220A2 (pt) agentes antibacterianos de tetrahidroquinolina tricíclica
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
EA201591192A1 (ru) Антибактериальные соединения
CY1118804T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
TH157385A (th) วิธีการสารเชิงซ้อนโอลิโกนิวคลีโอไทด์ คีเลต (Oligonucleotide chelate complex method)